Clincosm LogoSign in Get a demo

Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques

Sponsor
The Affiliated Hospital of Qingdao University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05088161
Collaborator
(none)
20
Enrollment
1
Location
10
Anticipated Duration (Months)
2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This study plan from the affiliated hospital of Qingdao university collected 20 cases of patients with pancreatic cancer pathological tissue samples and clinical data, including clinical diagnostic information, laboratory tests, imaging examination results and other information data), through high-throughput proteomic technology in pancreatic cancer pathological finding biomarkers, the bioinformatics analysis to explore the prognosis biomarkers.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    20 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques
    Actual Study Start Date :
    May 13, 2021
    Anticipated Primary Completion Date :
    Nov 12, 2021
    Anticipated Study Completion Date :
    Mar 12, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Differentially expressed proteins in tumor and paracancer tissues [180 Days]

      Two dimensional gel electrophoresis, mass spectrometry and other techniques were used to separate and compare pancreatic cancer tissues and normal adjacent tissues to search for differentially expressed proteins.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Patients of Chinese nationality, age and gender are not limited.

    • Pathologically confirmed pancreatic cancer patients.

    • Pathological specimens were archived tumor tissue samples after a diagnosis of pancreatic cancer.

    • Clinical diagnostic information was complete three months before sampling.

    Exclusion Criteria:
    • Patients with a second primary tumor.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Phase I Clinical Research Center Qingdao Shandong China 266003

    Sponsors and Collaborators

    • The Affiliated Hospital of Qingdao University

    Investigators

    • Principal Investigator: Yu Cao, Doctor, the study director of phase I clinical research center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    The Affiliated Hospital of Qingdao University
    ClinicalTrials.gov Identifier:
    NCT05088161
    Other Study ID Numbers:
    • JJDB-SR-2021-02
    First Posted:
    Oct 21, 2021
    Last Update Posted:
    Oct 21, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Oct 21, 2021